Furthermore, recent studies have shown that the use of intra-arterial tissue-type plasminogen activators after unsuccessful MT did not result in a higher risk of symptomatic intracranial hemorrhage or mortality, making it a low-risk bailout procedure [43, 44]. The gene discussed is PLAT; the disease is intracranial hemorrhage.